PEP in Acute Myocardial Infarction for Heart Attack

Phase-Based Progress Estimates
Heart AttackPEP in Acute Myocardial Infarction - Drug
21 - 85
All Sexes
What conditions do you have?

Study Summary

This trial will test the safety of a new drug for people who have had a heart attack.

Treatment Effectiveness

Study Objectives

1 Primary · 4 Secondary · Reporting Duration: Day 1 (Baseline/Screening) visit, Day 40 and Day 365

Day 365
Alloimmune Response
Day 365
Abdominal abnormalities
Day 40
Ejection fraction
Infarction scar size
Day 1
Obstetric Delivery

Trial Safety

Trial Design

1 Treatment Group

PEP in Acute Myocardial Infarction
1 of 1

Experimental Treatment

23 Total Participants · 1 Treatment Group

Primary Treatment: PEP in Acute Myocardial Infarction · No Placebo Group · Phase 1

PEP in Acute Myocardial Infarction
Experimental Group · 1 Intervention: PEP in Acute Myocardial Infarction · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: day 1 (baseline/screening) visit, day 40 and day 365

Who is running the clinical trial?

Christopher J. McLeodLead Sponsor
1 Previous Clinical Trials
24 Total Patients Enrolled
Guy S Reeder, MDPrincipal InvestigatorMayo Clinic

Eligibility Criteria

Age 21 - 85 · All Participants · 9 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You live within 90 miles of the study site.
You are aged 21-85 years.
You have a recent acute myocardial infarction (heart attack).
You have a QRS complex of ≥2 mm (0.2 mV) in men or ≥1.5 mm (0.
Angiographic evidence of TIMI 0 or TIMI 1 flow through culprit lesion prior to stent placement.
You have angiographic evidence of residual stenosis visually <30% after stent placement.